The sST2 biomarker serves as a fundamental prognostic marker in cardiovascular disease and for treatment monitoring in heart failure.
This review highlights the role of the ST2/IL-33 pathway, particularly sST2, as a prognostic and monitoring biomarker across various adult and pediatric cardiovascular diseases.
ST2 is a member of interleukin 1 receptor family with soluble sST2 and transmembrane ST2L isoforms. The ligand of ST2 is IL-33, which determines the activation of numerous intracytoplasmic mediators following the binding with ST2L and IL-1RAcP, leading to nuclear signal and cardiovascular effect. Differently, sST2 is released in the blood and works as a decoy receptor, binding IL-33 and blocking IL-33/ST2L interaction. sST2 is mainly involved in maintaining homeostasis and/or alterations of different tissues, as counterbalance/activation of IL-33/ST2L axis is typically involved in the development of fibrosis, tissue damage, inflammation and remodeling. sST2 has been described in different clinical reports as a fundamental prognostic marker in patients with cardiovascular disease, as well as marker for the treatment monitoring of patients with heart failure; however, further studies are needed to better elucidate its role. In this review we reported the current knowledge about its role in coronary artery disease, heart failure, heart transplantation, heart valve disease, pulmonary arterial hypertension, and cardiovascular interventions.
Brunetti et al. (Fri,) conducted a review in Adult and paediatric heart disease and transplantation. sST2 biomarker was evaluated. The sST2 biomarker serves as a fundamental prognostic marker in cardiovascular disease and for treatment monitoring in heart failure.